May 12 2020
Voyageur Pharmaceuticals Ltd. (the “Company” or “Voyageur”) is pleased to announce it has signed an LOI with an established international mining company (the “Counterparty”) that has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from large natural-occurring fullerene resources.
The technology to extract C-60 from natural fullerene deposits is ground-breaking and a first in this industry. “Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed,” states Brent Willis, CEO of Voyageur Pharmaceuticals.
“The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale,” continues Brent Willis.
The API, C-60, is a natural, highly effective super antioxidant, like more common antioxidants (Vitamin C, Vitamin A and Selenium). It scavenges toxic free radicals but it stands out as a notable anti-aging innovation because it selectively scavenges the reactive oxygen species that do the most damage to humans as opposed to just working by osmosis like a normal antioxidant. The anti-aging properties are exciting, as studies in animals have shown the potential to significantly extend life span and to slow the aging process.
Voyageur has begun work on its first C-60 product, C-60X, an immune system booster, natural health product, for daily consumption. Voyageur is creating a C-60 R&D Therapeutics division that will be focused on developing natural health products and drugs. For early cash flow, Voyageur will utilize our Calgary-based manufacturing partners for natural health product sales.
Highlights of C-60 Medical Applications
- Radio Graphic Contrast Media – Allowing drugs to be safer, more effective by using C-60 to be a transport system for iodine and gadolinium drugs.
- Anti Viral – Antiretroviral therapy (Influenza, HIV, HSV, CMV (1)), Studies show how C-60 has an ability to suppress viruses, minimising their effects on the body.
- Anti-bacterial inhibition (Antibiotics) – studies prove that C-60 can be used as an antibiotic.
- Anti Aging – Batti study showed that life span of rats almost doubled.
- Photosensitizers and Sonosensitizers (Cancer treatments). C-60 has been proven to work as a mechanism in photodynamic therapy to destroy cancer cells.
- Antioxidant Immune System Enhancer (Daily supplements for improved health) – C-60 is currently sold as an immune supplement. Voyageur is creating C-60X, an immune system daily supplement to help people increase their immune system function.
- Antitumor and Antimetastatic Agent Vaccines. Potential for vaccine development.
- EMFs Endohedral metallofullerenes (drug transport systems) C-60 can be used to transport drugs to the source of the disease.
- Cardiovascular Health, studies have shown that C-60 improves cardiovascular health
- Anti-Inflammatory Agents
- Sunscreen – Protection from Radiation-Induced Injury, Ionizing Radiation, and UVA; it helps repair damaged skin.
- Athletic Performance Enhancement – Studies report higher athletic performance and increased recovery from muscle strain due to intense work outs.
"The difficulty in processing of fullerenes has presented a major problem in the search for medicinal applications. This is the breakthrough that our partner has recently overcome. The patent-pending technology that can recover economic & high volumes of C-60 from natural fullerene mineral ores is a game changer. This opens the door for Voyageur to become the only company to have the capability to develop and mass produce C-60 based drugs and natural health products at a low cost & high volume,” says Brent Willis.
Voyageur plans to develop low cost C-60 radiographic contrast drugs, which encapsulate iodine, gadolinium, and other potential molecules. By utilizing C-60, we may be able to enhance the performance and create the safest radiographic contrast media in the marketplace. Studies have shown that MRI C-60 gadolinium contrast media has a gain of a 500-fold sensitivity on intravital MR Contrast Agents.
Essentially, a carbon-60 molecule is comprised of 60 carbon atoms which are arranged in a unique shape that can be thought of as a 'carbon cage' (like a soccer ball). This sphere makes it possible to be a carrier of other molecules creating a protective shield, allowing C-60 to be an excellent drug delivery vehicle in radiology and healthcare.
“This drug delivery system is quite unique to the pharmaceutical industry and our company is proud to begin the innovative steps to develop unique new delivery systems,” states Brent Willis.
It has long been known that effective delivery systems are of paramount importance in promoting drug efficacy. “This is not only a major milestone for our Company, but potentially a major breakthrough for the entire healthcare industry,” continues Willis. “The significance of the technological breakthrough, to extract natural fullerene from rock, may well pave the way for a low-cost evolution in the carbon-based health care market. Voyageur is the first company to begin to break down the barrier to market. The C-60 therapeutics division will enhance our Company’s ability to become more competitive in the radiographic contrast market and become a leader in the C-60 drug & natural health sector. Fullerene is a gateway for Voyageur to become a leader in a new and exciting carbon medicine field. We will continue to build our From The Earth To The Bottle strategy, to become a fully-integrated competitive force in the API mineral based pharmaceutical industry.”
The signed LOI for supply exclusivity will allow Voyageur to produce low cost & high-volume natural carbon-60 API for the pharmaceutical industry. This would allow Voyageur to be fully integrated in the C-60 market and become the only low-cost producer of fullerene based health care products. Voyageur is adding C-60 to its portfolio of active pharmaceutical ingredients (API) minerals for use in the radiographic contrast media markets. There are multiple applications for Fullerene based nano medicines in the healthcare industry, which Voyageur will further research and develop.
Due to confidentiality and pending patents, Voyageur cannot disclose at this time, the identity of the Counterparty.